載入...
Periodontal disease in a patient receiving Bevacizumab: a case report
INTRODUCTION: Bevacizumab is a monoclonal antibody that inhibits the action of vascular endothelial growth factor (VEGF) thereby acting as an angiogenesis inhibitor. As a result, supply of oxygen and nutrients to tissues is impaired and tumour cell growth is reduced. Reported side effects due to bev...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BioMed Central
2008
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2262909/ https://ncbi.nlm.nih.gov/pubmed/18271967 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1752-1947-2-47 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|